Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE

BACKGROUND: Monitoring of pancreatic neuroendocrine tumors (PanNET) undergoing peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE depends on changes in tumor size, which often occur late. Tumor growth rate (TGR) allows for quantitative assessment of the tumor kinetics expressed as %/...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettersson, Olof Joakim, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111309/
https://www.ncbi.nlm.nih.gov/pubmed/33875614
http://dx.doi.org/10.1530/EC-21-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111309/
https://www.ncbi.nlm.nih.gov/pubmed/33875614
http://dx.doi.org/10.1530/EC-21-0027

Ejemplares similares